As the mRNA-based vaccination technology has been progressing rapidly, the book is intended to be an end-to-end review series, covering everything from basic RNA biology and preclinical studies to the manufacturing strategy, clinical development and regulatory approval. It provides established RNA researchers and developers with updates on the latest advancements in the field and allows for a quick but comprehensive overview of this transformative technology, its application, and future potential.
Foreword - RNA technology overviewDong Yu (email@example.com) (GSK) & Frank Bähner (Frank.Baehner@curevac.com) (CureVac) – confirmed
Conventional mRNA-based technology & mode of action
Benjamin Petsch (firstname.lastname@example.org) (CureVac) – confirmed
Self-amplifying RNA-based technology & mode of action
Jeffrey Ulmer (email@example.com)/Dong Yu (firstname.lastname@example.org) (GSK) – confirmed
Delivery and formulation technologies
Yizhou Dong (email@example.com) (Ohio State) – confirmedRNA for infectious disease applications
Drew Weissman (firstname.lastname@example.org) (U Penn) – confirmed
RNA for other indications (immunotherapies/oncology, molecular therapies - a potential topic)
Tim Wagenaar (Timothy.Wagenaar@sanofi.com) (Sanofi) – tentatively confirmed, likely working with Biotech; Backup - Katalin Karikó (BioNTech)
Production and capabilities
Heinrich Haas (Heinrich.Haas@biontech.de) (Biontech) – waiting for response; Backup - Juan Andres (Moderna)
Tal Zaks (Tal.Zaks@modernatx.com) (Moderna) – tentatively confirmed; Backup - Anna Collén (AstraZeneca)
Other considerations (e.g., safety, regulatory issues, challenges)
Mark Tracy (email@example.com) (Tracy Bioconsulting) – waiting for response
Dr. Dong Yu currently is Senior Vice President of Research at Dynavax Technologies. Prior to joining Dynavax, Dr. Yu was the Head of Preclinical R&D US at GSK Vaccines. He received the PhD from University of Connecticut Health Center. He was a faculty member at Washington University in Saint Louis and the Head of Microbial Molecular Biology at Novartis Vaccines prior to joining GSK Vaccines in 2015. Dr. Yu authored over 40 publications in various journals and books. His publications reflect his research interests in virology, infectious diseases, and vaccines.
Dr. Benjamin Petsch, Senior Director Prophylactic Vaccine Research at CureVac AG, Benjamin Petsch joined CureVac in 2010 as a scientist in the vaccines department developing mRNA based vaccines against infectious diseases and is heading the department since 2013. He received his university degree from Ludwig-Maximilians-University of Munich and performed his doctoral thesis at the Friedrich-Loeffler-Institut, Tübingen, where he continued as a postdoc and research group leader working on mRNA vaccination against Influenza and on intervention of Influenza replication using small molecules. Dr. Petsch has a 10+ years scientific experience on mRNA based prophylactic vaccines.